Antiandrogenic effects of spironolactone: hormonal and ultrastructural studies in dogs and men.
A decrease in the level of plasma testosterone and an increase in the level of plasma progesterone were noted after spironolactone had been administered for 20 days in 5 patients with prostatic carcinoma, as well as in 8 male dogs. Electron microscopic observation disclosed myelin-like bodies in the cytoplasm of Leydig and adrenocortical cells in dogs, contributing to a resolution of the mode of antiandrogenic action of spironolactone.
D000311:Adrenal Glands / Q000648:ultrastructure; D000726:Androgen Antagonists / Q000494:pharmacology*; D000728:Androgens / Q000096:biosynthesis; D000818:Animals; D003593:Cytoplasm / Q000648:ultrastructure; D004285:Dogs; D006801:Humans; D007985:Leydig Cells / Q000648:ultrastructure; D008297:Male; D009929:Organ Size / Q000187:drug effects; D011374:Progesterone / Q000097:blood*; D011467:Prostate / Q000648:ultrastructure; D011471:Prostatic Neoplasms / Q000097:blood / Q000648:ultrastructure*; D013148:Spironolactone / Q000494:pharmacology*; D013739:Testosterone / Q000097:blood*
D000726:Androgen Antagonists; D000728:Androgens; D013148:Spironolactone; D013739:Testosterone; D011374:Progesterone